Hanmi Science Co.,Ltd
Financials
Valuation Metrics
Hanmi Science Co.,Ltd's Market Cap is ₩2.7T. At end of 2025 it was ₩2.5T. Ranked #159 of 2,436 in KR market (top 7%), #134 of 787 on KOSPI (top 17%), #3 of 96 in Health Care Equipment & Services (top 3%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.68T KRW | KR#159/2,436 Sec#3/96 |
| Revenue | 1.38T KRW | KR#327/2,436 Sec#1/96 |
| Net Income | 135.55B KRW | KR#177/2,436 Sec#1/96 |
| Total Assets | 1.49T KRW | KR#365/2,436 Sec#3/96 |
| Net Assets | 1.00T KRW | KR#286/2,436 Sec#3/96 |
| Employees | 453 | KR#539/2,436 Sec#12/96 |
| Value | ||
| P/E | 19.78x | KR#1,098/2,436 Sec#33/96 |
| P/B | 2.68x | KR#2,068/2,436 Sec#74/96 |
| PEG | 0.27x | KR#577/2,436 Sec#19/96 |
| P/S | 1.94x | KR#1,807/2,436 Sec#48/96 |
| EV/EBITDA | 18.95x | KR#981/2,436 Sec#29/96 |
| Profitability | ||
| ROE | 13.55% | KR#303/2,436 Sec#15/96 |
| ROA | 9.07% | KR#250/2,436 Sec#14/96 |
| Op. Margin | 10.53% | KR#461/2,436 Sec#28/96 |
| Revenue Growth | 6.49% | KR#1,104/2,436 Sec#55/96 |
| Earnings Growth | 72.95% | KR#487/2,436 Sec#19/96 |
| Financial Health | ||
| Debt Ratio | 49.48% | KR#177/2,436 Sec#7/96 |
| Total Debt | 186.72B KRW | KR#508/2,436 Sec#6/96 |
| Cash | 115.39B KRW | KR#420/2,436 Sec#3/96 |
| Current Ratio | 0.87x | KR#1,959/2,436 Sec#87/96 |
| Net Debt/EBITDA | 0.49x | KR#746/2,436 Sec#32/96 |
| Dividend | ||
| Div. Yield | 0.83% | KR#1,198/2,436 Sec#38/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -11.51% | KR#1,015/2,436 Sec#28/96 |
| 1M Return | 23.27% | KR#100/2,436 Sec#7/96 |
| From 52W High | -29.37% | KR#388/2,436 Sec#11/96 |
| 1Y MDD | -49.71% | KR#920/2,436 Sec#33/96 |
| Trading | ||
| Volume | 316,696 shares | KR#384/2,436 Sec#13/96 |
| Foreign Own. | 1.48% | KR#1,125/2,436 Sec#41/96 |
| Per Share | ||
| EPS | 1,989 KRW | KR#398/2,436 Sec#7/96 |
| BPS | 14,761 KRW | KR#668/2,436 Sec#11/96 |
Company Info
Hanmi Science, established in 1973, received approval for conversion to a holding company in 2011. In 2022, it merged with Hanmi Healthcare, adding a healthcare business division and transforming into an operating holding company. It generates profit through equity gains from subsidiaries, patent and trademark royalty income, healthcare business, and affiliate management, holding 8 subsidiaries including Hanmi Pharmaceutical. As an operating holding company, it is dedicated to discovering new growth engines, sharing new drug development risks, and establishing mid-to-long-term visions to lead the rapidly changing global healthcare market. Hanmi Science is headquartered in Hwaseong-si, Gyeonggi-do.